NEW YORK (
CHANGE IN RATINGS
upgraded to buy at TheStreet Ratings.
upgraded at Goldman to Buy, Goldman Sachs said. Company can deliver solid fee-related earnings growth. $17.50 price target.
(BLK - Get Report)
downgraded at Goldman to Neutral, Goldman Sachs said. Valuation call, based on a $203 price target.
added to TPL at Citigroup. $45 price target. Recent pull back is a good entry point.
upgraded at Goldman to Buy, Goldman Sachs said. $19 price target. Company has solid fundraising potential in real estate and credit markets.
downgraded at Stifel from Hold to Sell, Stifel Nicolaus said. Valuation call.
downgraded at Citigroup to Neutral from Buy, Citigroup said. $19 price target. Easy margin expansion is done.
Dell downgraded at Needham from Buy to Hold, Needham said. $17 price target. Stock will likely remain rangebound, given near-term growth headwinds.
downgraded at Hudson Square from Buy to Hold, Hudson Square Research said. Dividend cut takes some luster off the stock.
downgraded at UBS to Neutral from Buy, UBS said. $64 price target. Valuation call.
downgraded at Piper from Overweight to Neutral, Piper Jaffray said. Valuation call, based on an $11 price target.
downgraded at Needham from Buy to Hold, Needham said. Valuation call.
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. Company could be hurt by higher feedstock ore costs. $23 price target.
downgraded at Credit Suisse from Outperform to Neutral, Credit Suisse said. $43 price target. Majority of the company's sales are in low-growth areas.
Medtronic downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $41 price target. Company faces continued growth headwinds.
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $45 price target. Company cut its production guidance.
rated new Buy at ThinkEquity. $39 price target. Company should continue to execute and remain an industry leader.
upgraded at BMO to Outperform, BMO Capital said. $36 price target. Visibility is improving for the second half of the year and 2013.